These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 27039356

  • 21. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
    Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Atyabi F, Asouri M, Ahmadi AA, Hadizadeh F.
    J Control Release; 2015 Jul 10; 209():88-100. PubMed ID: 25912964
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
    Holmboe S, Hansen PL, Thisgaard H, Block I, Müller C, Langkjær N, Høilund-Carlsen PF, Olsen BB, Mollenhauer J.
    PLoS One; 2017 Jul 10; 12(5):e0178286. PubMed ID: 28542563
    [Abstract] [Full Text] [Related]

  • 23. Smart bomb AS1411 aptamer-functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer.
    Barzegar Behrooz A, Nabavizadeh F, Adiban J, Shafiee Ardestani M, Vahabpour R, Aghasadeghi MR, Sohanaki H.
    Clin Exp Pharmacol Physiol; 2017 Jan 10; 44(1):41-51. PubMed ID: 27626786
    [Abstract] [Full Text] [Related]

  • 24. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
    Khare V, Singh A, Mahajan G, Alam N, Kour S, Gupta M, Kumar A, Singh G, Singh SK, Saxena AK, Mondhe DM, Gupta PN.
    Eur J Pharm Sci; 2016 Sep 20; 92():183-93. PubMed ID: 27404580
    [Abstract] [Full Text] [Related]

  • 25. Surface modification of hollow gold nanoparticles conducted by incorporating cancer cell membrane and AS1411 aptamer, aiming to achieve a dual-targeted therapy for colorectal cancer.
    Hassibian S, Taghdisi SM, Jamshidi Z, Samie A, Alinezhad Nameghi M, Shayan M, Farrokhi N, Alibolandi M, Ramezani M, Dehnavi SM, Abnous K.
    Int J Pharm; 2024 Apr 25; 655():124036. PubMed ID: 38522491
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells.
    Vandghanooni S, Eskandani M, Barar J, Omidi Y.
    Int J Pharm; 2020 Jan 05; 573():118729. PubMed ID: 31705975
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Aptamer-modified PLGA nanoparticle delivery of triplex forming oligonucleotide for targeted prostate cancer therapy.
    Jiao J, Zou Q, Zou MH, Guo RM, Zhu S, Zhang Y.
    Neoplasma; 2016 Jan 05; 63(4):569-75. PubMed ID: 27268920
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
    Alibolandi M, Ramezani M, Sadeghi F, Abnous K, Hadizadeh F.
    Int J Pharm; 2015 Feb 01; 479(1):241-51. PubMed ID: 25529433
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
    Esawi E, Alshaer W, Mahmoud IS, Alqudah DA, Azab B, Awidi A.
    Int J Mol Sci; 2021 Nov 30; 22(23):. PubMed ID: 34884745
    [Abstract] [Full Text] [Related]

  • 34. Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers.
    Abnous K, Danesh NM, Ramezani M, Charbgoo F, Bahreyni A, Taghdisi SM.
    Expert Opin Drug Deliv; 2018 Nov 30; 15(11):1045-1052. PubMed ID: 30269603
    [Abstract] [Full Text] [Related]

  • 35. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
    Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ.
    Proc Natl Acad Sci U S A; 2008 Nov 11; 105(45):17356-61. PubMed ID: 18978032
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging.
    Chauhan M, Sonali, Shekhar S, Yadav B, Garg V, Dutt R, Mehata AK, Goswami P, Koch B, Muthu MS, Singh RP.
    Biomater Adv; 2024 Jun 11; 160():213833. PubMed ID: 38564997
    [Abstract] [Full Text] [Related]

  • 38. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
    Wu R, Zhang Z, Wang B, Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L.
    Drug Des Devel Ther; 2020 Jun 11; 14():2249-2261. PubMed ID: 32606595
    [Abstract] [Full Text] [Related]

  • 39. PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor.
    Shakib Z, Mahmoudi A, Moosavian SA, Malaekeh-Nikouei B.
    Drug Dev Ind Pharm; 2022 Feb 11; 48(2):69-78. PubMed ID: 35758194
    [Abstract] [Full Text] [Related]

  • 40. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
    Devulapally R, Foygel K, Sekar TV, Willmann JK, Paulmurugan R.
    ACS Appl Mater Interfaces; 2016 Dec 14; 8(49):33412-33422. PubMed ID: 27960411
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.